Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Valderrabano

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
European Journal of Endocrinology|February 24, 2016
Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker testsPablo Valderrabano, Marino E Leon, Barbara A Centeno, et al.
Thyroid : Official Journal of the American Thyroid Association|June 1, 2018
Thyroid Nodules with Indeterminate Cytology: Utility of the American Thyroid Association Sonographic Patterns for Cancer Risk StratificationPablo Valderrabano, Melissa J McGettigan, Cesar A Lam, et al.
JAMA Otolaryngology-- Head & Neck Surgery|July 21, 2018
Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid NodulesPablo Valderrabano, Laila Khazai, Zachary J Thompson, et al.
Endocrine|June 23, 2023
Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?Marta Araujo-Castro, Felicia A Hanzu, Eider Pascual-Corrales, et al.
Thyroid : Official Journal of the American Thyroid Association|June 22, 2016
Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for MalignancyPablo Valderrabano, Jaime Montilla-Soler, Mathew Mifsud, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 1, 2022
Evaluation of Body Composition in Patients With and Without Adrenal Tumors and Without Overt Hypersecretory SyndromesMarta Araujo-Castro, Eider Pascual-Corrales, Ana M García Cano, et al.
Head & Neck|April 7, 2018
Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodulesPablo Valderrabano, Laila Khazai, Zachary J Thompson, et al.
Endocrine-Related Cancer|January 21, 2017
Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytologyPablo Valderrabano, Laila Khazai, Marino E Leon, et al.
Hormones (Athens, Greece)|July 17, 2021
Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomasMarta Araujo-Castro, Paola Parra Ramírez, Cristina Robles Lázaro, et al.
Thyroid : Official Journal of the American Thyroid Association|August 16, 2017
Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological ApproachPablo Valderrabano, Laila Khazai, Zachary J Thompson, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
European Journal of Endocrinology|February 24, 2016
Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker testsPablo Valderrabano, Marino E Leon, Barbara A Centeno, et al.
Thyroid : Official Journal of the American Thyroid Association|June 1, 2018
Thyroid Nodules with Indeterminate Cytology: Utility of the American Thyroid Association Sonographic Patterns for Cancer Risk StratificationPablo Valderrabano, Melissa J McGettigan, Cesar A Lam, et al.
JAMA Otolaryngology-- Head & Neck Surgery|July 21, 2018
Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid NodulesPablo Valderrabano, Laila Khazai, Zachary J Thompson, et al.
Endocrine|June 23, 2023
Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?Marta Araujo-Castro, Felicia A Hanzu, Eider Pascual-Corrales, et al.
Thyroid : Official Journal of the American Thyroid Association|June 22, 2016
Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for MalignancyPablo Valderrabano, Jaime Montilla-Soler, Mathew Mifsud, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|December 1, 2022
Evaluation of Body Composition in Patients With and Without Adrenal Tumors and Without Overt Hypersecretory SyndromesMarta Araujo-Castro, Eider Pascual-Corrales, Ana M García Cano, et al.
Head & Neck|April 7, 2018
Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodulesPablo Valderrabano, Laila Khazai, Zachary J Thompson, et al.
Endocrine-Related Cancer|January 21, 2017
Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytologyPablo Valderrabano, Laila Khazai, Marino E Leon, et al.
Hormones (Athens, Greece)|July 17, 2021
Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomasMarta Araujo-Castro, Paola Parra Ramírez, Cristina Robles Lázaro, et al.
Thyroid : Official Journal of the American Thyroid Association|August 16, 2017
Cancer Risk Stratification of Indeterminate Thyroid Nodules: A Cytological ApproachPablo Valderrabano, Laila Khazai, Zachary J Thompson, et al.
Pageof 3